Q1 Fiscal Year Ending March 2027 Financial Summary (Japan GAAP) [Consolidated]

Overview of Results

For the quarterly cumulative consolidated period, net sales were 3,659,068 thousand yen, up 14.4% YoY, and operating profit rose substantially to 163,500 thousand yen. Ordinary income was 156,383 thousand yen, and net income attributable to owners of the parent rose to 136,032 thousand yen, with significant improvements. Although the Discoveries/Drug Discovery Support segment remained in the red, the loss narrowed. The Investment & Consulting business saw a substantial increase in both sales and profit due to a recovery in e-commerce and large orders. The company will pursue profitability improvements through thorough cost management across the group.

Outlook and Asset Position

Full-year earnings forecast is unchanged from the May 2026 forecast. The financial condition remains at appropriate levels for current assets and liabilities, with an equity ratio of 50.1% maintaining financial health. No new investment plans have been disclosed, but policies continue toward streamlining operations and reducing costs. An earnings briefing is scheduled, and supplementary materials will be provided; attention will be on future order momentum and progress in non-clinical trials.